3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, Large B-Cell, Diffuse
5
Prostatic Neoplasms
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Lymphoma
2
Triple Negative Breast Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Immunoblastic Lymphadenopathy
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Adenocarcinoma
1
Interventions
fludarabine phosphate
6
Peripheral Blood Stem Cell Transplantation
5
Rituximab
4
Mycophenolic Acid
4
Cyclosporine
4
Cyclophosphamide
4
romidepsin
3
Whole-Body Irradiation
3
Methotrexate
3
Everolimus
3
Busulfan
3
durvalumab
2
Vorinostat
2
Vincristine
2
Tacrolimus
2
Photopheresis
2
Immunoglobulin G
2
Filgrastim
2
Etoposide
2
Disulfides
2
Brentuximab Vedotin
2
Bortezomib
2
veliparib
1
tremelimumab
1
tazarotenic acid
1
tazarotene
1
poly ICLC
1
pembrolizumab
1
navitoclax
1
mogamulizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, T-Cell, Cutaneous
×
Prednisolone
×
Clear all
NCT01198665
2015-03-03
RADCHOP
Samsung Medical Center
Phase 1/2
Completed
46 enrolled